Human Nucleotide Binding Oligomerization Domain Containing Protein 2 CLIA Kit | NOD2 clia kit

Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) CLIA Kit

Cat. Num. AAA2031858

• Gene Names: NOD2; CD; ACUG; BLAU; IBD1; NLRC2; NOD2B; CARD15; CLR16.3; PSORAS1
• Reactivity: Human
• Synonyms: Nucleotide Binding Oligomerization Domain Containing Protein 2; Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) CLIA Kit; CD; ACUG; BLAU; CARD15; CLR16.3; IBD1; NLRC2; NOD2B; PSORAS1; Caspase recruitment domain-containing protein 15; Inflammatory bowel disease protein 1; NOD2 clia kit

• Reactivity: Human
• Specificity: This assay has high sensitivity and excellent specificity for detection of Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2).; No significant cross-reactivity or interference between Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) and analogues was observed.
• Sequence Length: 1040

• Assay Type: Double-antibody Sandwich
• Samples: Tissue homogenates, Cell lysates and Other Biological Fluids
• Detection Range: 41.2-30,000pg/mL
• Sensitivity: < 17.4pg/mL
• Application: Chemiluminescent immunoassay for Antigen Detection.
• Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) were tested 20 times on one plate, respectively.
• Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) were tested on 3 different plates, 8 replicates in each plate.
• CV(%) =: SD/meanX100
• Intra-Assay: CV<10%
• Inter-Assay: CV<12%
• Preparation and Storage: The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. ; To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Typical Testing Data/Standard Curve

Related Product Information for NOD2 clia kit

The microplate provided in this kit has been pre-coated with an antibody specific to Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2). Standards or samples are then added to the appropriate microplate wells with a biotin-conjugated antibody specific to Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is proportional to the Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) level in the sample or standard.;

Product Categories/Family for NOD2 clia kit

Signal Transduction

NCBI and Uniprot Product Information

• NCBI GI #: 11545912
• NCBI GeneID: 64127
• NCBI Accession #: NP_071445.1
• NCBI GenBank Nucleotide #: NM_022162.2
• Molecular Weight: 22,403 Da
• NCBI Official Full Name: nucleotide-binding oligomerization domain-containing protein 2 isoform 1
• NCBI Official Synonym Full Names: nucleotide binding oligomerization domain containing 2
• NCBI Official Symbol: NOD2
• NCBI Official Synonym Symbols: CD; ACUG; BLAU; IBD1; NLRC2; NOD2B; CARD15; CLR16.3; PSORAS1
• NCBI Protein Information: nucleotide-binding oligomerization domain-containing protein 2
• UniProt Protein Name: Nucleotide-binding oligomerization domain-containing protein 2
• Protein Family: Nucleotide-binding oligomerization domain-containing protein
• UniProt Gene Name: NOD2
• UniProt Synonym Gene Names: CARD15; IBD1
• UniProt Entry Name: NOD2_HUMAN

NCBI Description

This gene is a member of the Nod1/Apaf-1 family and encodes a protein with two caspase recruitment (CARD) domains and six leucine-rich repeats (LRRs). The protein is primarily expressed in the peripheral blood leukocytes. It plays a role in the immune response to intracellular bacterial lipopolysaccharides (LPS) by recognizing the muramyl dipeptide (MDP) derived from them and activating the NFKB protein. Mutations in this gene have been associated with Crohn disease and Blau syndrome. Alternatively spliced transcript variants encoding distinct isoforms have been found for this gene. [provided by RefSeq, Jun 2014]

Uniprot Description

NOD2: Induces NF-kappa-B via RICK (CARDIAK, RIP2) and IKK- gamma. Confers responsiveness to intracellular bacterial lipopolysaccharides (LPS). Defects in NOD2 are the cause of Blau syndrome (BS). BS is a rare autosomal dominant disorder characterized by early-onset granulomatous arthritis, uveitis and skin rash. Defects in NOD2 are a cause of susceptibility to inflammatory bowel disease type 1 (IBD1). IBD1 is a chronic, relapsing inflammation of the gastrointestinal tract with a complex etiology. It is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may affect any part of the gastrointestinal tract from the mouth to the anus, but most frequently it involves the terminal ileum and colon. Bowel inflammation is transmural and discontinuous; it may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints. Defects in NOD2 are the cause of sarcoidosis early-onset (EOS). EOS is a form of sarcoidosis manifesting in children younger than 4 years of age. Sarcoidosis is an idiopathic, systemic, inflammatory disease characterized by the formation of immune granulomas in involved organs. Granulomas predominantly invade the lungs and the lymphatic system, but also skin, liver, spleen, eyes and other organs may be involved. Early- onset sarcoidosis is quite rare and has a distinct triad of skin, joint and eye disorders, without apparent pulmonary involvement. Compared with an asymptomatic and sometimes naturally disappearing course of the disease in older children, early-onset sarcoidosis is progressive and in many cases causes severe complications, such as blindness, joint destruction and visceral involvement. 2 isoforms of the human protein are produced by alternative initiation.

Chromosomal Location of Human Ortholog: 16q21

Cellular Component: basolateral plasma membrane; cell surface; cytoplasm; cytoskeleton; cytosol; plasma membrane; protein complex; signalosome; vesicle

Molecular Function: actin binding; ATP binding; CARD domain binding; enzyme binding; Hsp70 protein binding; Hsp90 protein binding; muramyl dipeptide binding; peptidoglycan binding; protein binding; protein kinase binding

Biological Process: activation of MAPK activity; activation of NF-kappaB transcription factor; cytokine production during immune response; cytokine secretion during immune response; defense response; defense response to bacterium; defense response to Gram-positive bacterium; detection of bacterium; detection of biotic stimulus; detection of muramyl dipeptide; immunoglobulin production during immune response; inhibition of NF-kappaB transcription factor; innate immune response; innate immune response in mucosa; JNK cascade; maintenance of gastrointestinal epithelium; MyD88-dependent toll-like receptor signaling pathway; MyD88-independent toll-like receptor signaling pathway; negative regulation of inflammatory response to antigenic stimulus; negative regulation of interferon-gamma production; negative regulation of interleukin-12 production; negative regulation of interleukin-18 production; negative regulation of interleukin-2 production; negative regulation of T cell mediated immunity; negative regulation of toll-like receptor 2 signaling pathway; negative regulation of tumor necrosis factor production; positive regulation of B cell activation; positive regulation of biosynthetic process of antibacterial peptides active against Gram-positive bacteria; positive regulation of dendritic cell antigen processing and presentation; positive regulation of epithelial cell proliferation; positive regulation of gamma-delta T cell activation; positive regulation of humoral immune response mediated by circulating immunoglobulin; positive regulation of I-kappaB kinase/NF-kappaB cascade; positive regulation of interleukin-1 beta production; positive regulation of interleukin-1 beta secretion; positive regulation of interleukin-10 production; positive regulation of interleukin-12 production; positive regulation of interleukin-17 production; positive regulation of interleukin-6 production; positive regulation of interleukin-8 production; positive regulation of JNK cascade; positive regulation of nitric-oxide synthase biosynthetic process; positive regulation of Notch signaling pathway; positive regulation of oxidoreductase activity; positive regulation of peptidyl-tyrosine phosphorylation; positive regulation of phagocytosis; positive regulation of phosphoinositide 3-kinase activity; positive regulation of stress-activated MAPK cascade; positive regulation of T-helper 2 type immune response; positive regulation of transcription from RNA polymerase II promoter; positive regulation of tumor necrosis factor production; protein oligomerization; regulation of inflammatory response; response to exogenous dsRNA; response to lipopolysaccharide; response to muramyl dipeptide; stress-activated MAPK cascade; toll-like receptor 10 signaling pathway; toll-like receptor 2 signaling pathway; toll-like receptor 3 signaling pathway; toll-like receptor 4 signaling pathway; toll-like receptor 5 signaling pathway; toll-like receptor 9 signaling pathway; toll-like receptor signaling pathway

Disease: Blau Syndrome; Inflammatory Bowel Disease 1; Psoriatic Arthritis, Susceptibility To; Sarcoidosis, Early-onset